Tamoxifen regulation of sphingolipid metabolism - Therapeutic implications

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1851, Issue 9, 2015, Pages 1134-1145

  Morad, Samy A F ^a,b,c   Cabot, Myles C ^a,b  

^a EAST CAROLINA UNIVERSITY   (United States)

^b East Carolina Diabetes and Obesity Institute   (United States)

^c South Valley University   (Egypt)

Author keywords

Acid ceramidase; Glucosylceramide synthase; Multidrug resistance; P glycoprotein; Sphingolipid; Tamoxifen

Indexed keywords

1,1,2 TRIPHENYLETHYLENE DERIVATIVE; ACID CERAMIDASE; CERAMIDE; CERAMIDE GLUCOSYLTRANSFERASE; ESTROGEN RECEPTOR; MULTIDRUG RESISTANCE PROTEIN; POSTCOITUS CONTRACEPTIVE AGENT; SPHINGOLIPID; TAMOXIFEN; AFIMOXIFENE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; LYSOPHOSPHOLIPID; N-DESMETHYLTAMOXIFEN; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; ENZYME ACTIVITY; GLYCOSYLATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SPHINGOLIPID METABOLISM; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BIOTRANSFORMATION; BREAST NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; HYDROLYSIS; LIPID METABOLISM; METABOLISM; PATHOLOGY;

ACID CERAMIDASE; ANTINEOPLASTIC AGENTS, HORMONAL; BIOTRANSFORMATION; BREAST NEOPLASMS; CERAMIDES; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; HYDROLYSIS; LIPID METABOLISM; LYSOPHOSPHOLIPIDS; SPHINGOSINE; TAMOXIFEN;

EID: 84930226591     PISSN: 13881981     EISSN: 18792618     Source Type: Journal    
DOI: 10.1016/j.bbalip.2015.05.001     Document Type: Review

References (163)

1. J.P. Truman, M. Garcia-Barros, L.M. Obeid, and Y.A. Hannun Evolving concepts in cancer therapy through targeting sphingolipid metabolism Biochim. Biophys. Acta 1841 2014 1174 1188
2. S.A. Morad, and M.C. Cabot Ceramide-orchestrated signalling in cancer cells Nat. Rev. Cancer 13 2013 51 65
3. S.A. Saddoughi, and B. Ogretmen Diverse functions of ceramide in cancer cell death and proliferation Adv. Cancer Res. 117 2013 37 58
4. Y. Lavie, H. Cao, S.L. Bursten, A.E. Giuliano, and M.C. Cabot Accumulation of glucosylceramides in multidrug-resistant cancer cells J. Biol. Chem. 271 1996 19530 19536
5. H. Morjani, N. Aouali, R. Belhoussine, R.J. Veldman, T. Levade, and M. Manfait Elevation of glucosylceramide in multidrug-resistant cancer cells and accumulation in cytoplasmic droplets Int. J. Cancer 94 2001 157 165
6. G. Gutierrez-Iglesias, Y. Hurtado, I. Palma-Lara, and R. Lopez-Marure Resistance to the antiproliferative effect induced by a short-chain ceramide is associated with an increase of glucosylceramide synthase, P-glycoprotein, and multidrug-resistance gene-1 in cervical cancer cells Cancer Chemother. Pharmacol. 74 2014 809 817
7. P. Xie, Y.F. Shen, Y.P. Shi, S.M. Ge, Z.H. Gu, J. Wang, H.J. Mu, B. Zhang, W.Z. Qiao, and K.M. Xie Overexpression of glucosylceramide synthase in associated with multidrug resistance of leukemia cells Leuk. Res. 32 2008 475 480
8. Y.Y. Liu, G.A. Patwardhan, P. Xie, X. Gu, A.E. Giuliano, and M.C. Cabot Glucosylceramide synthase, a factor in modulating drug resistance, is overexpressed in metastatic breast carcinoma Int. J. Oncol. 39 2011 425 431
9. V. Gouaze-Andersson, J.Y. Yu, A.J. Kreitenberg, A. Bielawska, A.E. Giuliano, and M.C. Cabot Ceramide and glucosylceramide upregulate expression of the multidrug resistance gene MDR1 in cancer cells Biochim. Biophys. Acta 1771 2007 1407 1417
10. Y.Y. Liu, T.Y. Han, A.E. Giuliano, and M.C. Cabot Ceramide glycosylation potentiates cellular multidrug resistance FASEB J. 15 2001 719 730
11. Y. Baran, J. Bielawski, U. Gunduz, and B. Ogretmen Targeting glucosylceramide synthase sensitizes imatinib-resistant chronic myeloid leukemia cells via endogenous ceramide accumulation J. Cancer Res. Clin. Oncol. 137 2011 1535 1544
12. Y.H. Zeidan, R.W. Jenkins, J.B. Korman, X. Liu, L.M. Obeid, J.S. Norris, and Y.A. Hannun Molecular targeting of acid ceramidase: implications to cancer therapy Curr. Drug Targets 9 2008 653 661
13. L. Camacho, O. Meca-Cortes, J.L. Abad, S. Garcia, N. Rubio, A. Diaz, T. Celia-Terrassa, F. Cingolani, R. Bermudo, P.L. Fernandez, J. Blanco, A. Delgado, J. Casas, G. Fabrias, and T.M. Thomson Acid ceramidase as a therapeutic target in metastatic prostate cancer J. Lipid Res. 54 2013 1207 1220
14. X. Liu, J.C. Cheng, L.S. Turner, S. Elojeimy, T.H. Beckham, A. Bielawska, T.E. Keane, Y.A. Hannun, and J.S. Norris Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy Expert Opin. Ther. Targets 13 2009 1449 1458
15. K.A. Orr Gandy, and L.M. Obeid Targeting the sphingosine kinase/sphingosine 1-phosphate pathway in disease: review of sphingosine kinase inhibitors Biochim. Biophys. Acta 1831 2013 157 166
16. N.C. Hait, C.A. Oskeritzian, S.W. Paugh, S. Milstien, and S. Spiegel Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases Biochim. Biophys. Acta 1758 2006 2016 2026
17. A. Senchenkov, D.A. Litvak, and M.C. Cabot Targeting ceramide metabolism - a strategy for overcoming drug resistance J. Natl. Cancer Inst. 93 2001 347 357
18. A. Abe, N.S. Radin, J.A. Shayman, L.L. Wotring, R.E. Zipkin, R. Sivakumar, J.M. Ruggieri, K.G. Carson, and B. Ganem Structural and stereochemical studies of potent inhibitors of glucosylceramide synthase and tumor cell growth J. Lipid Res. 36 1995 611 621
19. M.C. Cabot, A.E. Giuliano, A. Volner, and T.Y. Han Tamoxifen retards glycosphingolipid metabolism in human cancer cells FEBS Lett. 394 1996 129 131
20. A. van Helvoort, A.J. Smith, H. Sprong, I. Fritzsche, A.H. Schinkel, P. Borst, and G. van Meer MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine Cell 87 1996 507 517
21. Y.C. Lim, Z. Desta, D.A. Flockhart, and T.C. Skaar Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen Cancer Chemother. Pharmacol. 55 2005 471 478
22. E.A. Lien, E. Solheim, and P.M. Ueland Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment Cancer Res. 51 1991 4837 4844
23. C. Fabian, L. Tilzer, and L. Sternson Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: correlation with blood levels in patients with metastatic breast cancer Biopharm. Drug Dispos. 2 1981 381 390
24. E. Bignon, M. Pons, J.C. Dore, J. Gilbert, T. Ojasoo, J.F. Miquel, J.P. Raynaud, and A. Crastes de Paulet Influence of di- and tri-phenylethylene estrogen/antiestrogen structure on the mechanisms of protein kinase C inhibition and activation as revealed by a multivariate analysis Biochem. Pharmacol. 42 1991 1373 1383
25. V.C. Jordan Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents J. Med. Chem. 46 2003 1081 1111
26. V.C. Jordan Biochemical pharmacology of antiestrogen action Pharmacol. Rev. 36 1984 245 276
27. V.C. Jordan Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions J. Med. Chem. 46 2003 883 908
28. M.J. Meegan, and D.G. Lloyd Advances in the science of estrogen receptor modulation Curr. Med. Chem. 10 2003 181 210
29. P. de Medina, G. Favre, and M. Poirot Multiple targeting by the antitumor drug tamoxifen: a structure-activity study Curr. Med. Chem. Anticancer Agents 4 2004 491 508
30. D.J. Bentrem, and V. Craig Jordan Tamoxifen, raloxifene and the prevention of breast cancer Minerva Endocrinol. 27 2002 127 139
31. J.A. Kellen Tamoxifen: Beyond the Antiestrogen Birkhäuser, Boston 1996
32. H. Wiseman Tamoxifen as an antioxidant and cardioprotectant Biochem. Soc. Symp. 61 1995 209 219
33. G.E. Christodoulakos, I.V. Lambrinoudaki, and D.C. Botsis The cardiovascular effects of selective estrogen receptor modulators Ann. N. Y. Acad. Sci. 1092 2006 374 384
34. E. Hernandez, R. Valera, E. Alonzo, M. Bajares-Lilue, R. Carlini, F. Capriles, R. Martinis, E. Bellorin-Font, and J.R. Weisinger Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis Kidney Int. 63 2003 2269 2274
35. T. Saarto, C. Blomqvist, C. Ehnholm, M.R. Taskinen, and I. Elomaa Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer J. Clin. Oncol. 14 1996 429 433
36. M. Morales, N. Santana, A. Soria, A. Mosquera, J. Ordovas, J. Novoa, P. Betancor, P.F. Valeron, B. Diaz-Chico, and R. Chirino Effects of tamoxifen on serum lipid and apolipoprotein levels in postmenopausal patients with breast cancer Breast Cancer Res. Treat. 40 1996 265 270
37. H. Wiseman Tamoxifen: new membrane-mediated mechanisms of action and therapeutic advances Trends Pharmacol. Sci. 15 1994 83 89
38. E.E. Jolly, N.H. Bjarnason, P. Neven, L. Plouffe Jr., C.C. Johnston Jr., S.D. Watts, C.D. Arnaud, T.M. Mason, G. Crans, R. Akers, and M.W. Draper Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years Menopause 10 2003 337 344
39. S.S. Ko, and V.C. Jordan Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene Expert. Opin. Pharmacother. 12 2011 657 674
40. E.M. Lewiecki Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis J. Womens Health (Larchmt) 18 2009 1615 1626
41. B. Arun, M. Anthony, and B. Dunn The search for the ideal SERM Expert. Opin. Pharmacother. 3 2002 681 691
42. B.L. Clarke, and S. Khosla New selective estrogen and androgen receptor modulators Curr. Opin. Rheumatol. 21 2009 374 379
43. P. de Medina, B.L. Payre, J. Bernad, I. Bosser, B. Pipy, S. Silvente-Poirot, G. Favre, J.C. Faye, and M. Poirot Tamoxifen is a potent inhibitor of cholesterol esterification and prevents the formation of foam cells J. Pharmacol. Exp. Ther. 308 2004 1165 1173
44. J. Kusunoki, D.K. Hansoty, K. Aragane, J.T. Fallon, J.J. Badimon, and E.A. Fisher Acyl-CoA:cholesterol acyltransferase inhibition reduces atherosclerosis in apolipoprotein E-deficient mice Circulation 103 2001 2604 2609
45. S. Peng, W. Guo, J.D. Morrisett, M.T. Johnstone, and J.A. Hamilton Quantification of cholesteryl esters in human and rabbit atherosclerotic plaques by magic-angle spinning (13)C-NMR Arterioscler. Thromb. Vasc. Biol. 20 2000 2682 2688
46. S. Bemlih, M.D. Poirier, and A. El Andaloussi Acyl-coenzyme A: cholesterol acyltransferase inhibitor Avasimibe affect survival and proliferation of glioma tumor cell lines Cancer Biol. Ther. 9 2010 1025 1032
47. C.J. Antalis, A. Uchida, K.K. Buhman, and R.A. Siddiqui Migration of MDA-MB-231 breast cancer cells depends on the availability of exogenous lipids and cholesterol esterification Clin. Exp. Metastasis 28 2011 733 741
48. T. Hayon, L. Atlas, E. Levy, A. Dvilansky, O. Shpilberg, and I. Nathan Multifactorial activities of nonsteroidal antiestrogens against leukemia Cancer Detect. Prev. 27 2003 389 396
49. L.Z. Shen, Y.B. Hua, X.M. Yu, Q. Xu, T. Chen, J.H. Wang, and W.X. Wu Tamoxifen can reverse multidrug resistance of colorectal carcinoma in vivo World J. Gastroenterol. 11 2005 1060 1064
50. Y. Nakayama, H. Sakamoto, K. Satoh, and T. Yamamoto Tamoxifen and gonadal steroids inhibit colon cancer growth in association with inhibition of thymidylate synthase, survivin and telomerase expression through estrogen receptor beta mediated system Cancer Lett. 161 2000 63 71
51. D.J. Lindner, and E.C. Borden Synergistic antitumor effects of a combination of interferon and tamoxifen on estrogen receptor-positive and receptor-negative human tumor cell lines in vivo and in vitro J. Interferon Cytokine Res. 17 1997 681 693
52. P. Lointier, D.M. Wildrick, and B.M. Boman Growth effects of tamoxifen on Lovo colon carcinoma cells and cultured cells from normal colonic mucosa Anticancer Res. 12 1992 1523 1525
53. O.M. Dorchies, J. Reutenauer-Patte, E. Dahmane, H.M. Ismail, O. Petermann, O. Patthey-Vuadens, S.A. Comyn, E. Gayi, T. Piacenza, R.J. Handa, L.A. Decosterd, and U.T. Ruegg The anticancer drug tamoxifen counteracts the pathology in a mouse model of duchenne muscular dystrophy Am. J. Pathol. 182 2013 485 504
54. S.S. Taneja, M.R. Smith, J.T. Dalton, S. Raghow, G. Barnette, M. Steiner, and K.A. Veverka Toremifene - a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy Expert Opin. Invest. Drugs 15 2006 293 305
55. S. Raghow, M.Z. Hooshdaran, S. Katiyar, and M.S. Steiner Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model Cancer Res. 62 2002 1370 1376
56. P.N. Lara Jr., D.R. Gandara, J. Longmate, P.H. Gumerlock, D.H. Lau, M.J. Edelman, R. Gandour-Edwards, P.C. Mack, V. Israel, J. Raschko, P. Frankel, E.A. Perez, H.J. Lenz, and J.H. Doroshow Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial Cancer Chemother. Pharmacol. 48 2001 22 28
57. J.C. Ko, H.C. Chiu, J.J. Syu, Y.J. Jian, C.Y. Chen, Y.T. Jian, Y.J. Huang, T.Y. Wo, and Y.W. Lin Tamoxifen enhances erlotinib-induced cytotoxicity through down-regulating AKT-mediated thymidine phosphorylase expression in human non-small-cell lung cancer cells Biochem. Pharmacol. 88 2014 119 127
58. W.T. Couldwell, J.P. Antel, and V.W. Yong Protein kinase C activity correlates with the growth rate of malignant gliomas: Part II. Effects of glioma mitogens and modulators of protein kinase C Neurosurgery 31 1992 717 724 (discussion 724)
59. Y. Lavie, Z.C. Zhang, H.T. Cao, T.Y. Han, R.C. Jones, Y.Y. Liu, M. Jarman, I.R. Hardcastle, A.E. Giuliano, and M.C. Cabot Tamoxifen induces selective membrane association of protein kinase C epsilon in MCF-7 human breast cancer cells Int. J. Cancer 77 1998 928 932
60. M.C. Cabot, Z.C. Zhang, and A.E. Giuliano Tamoxifen elicits rapid transmembrane lipid signal responses in human breast cancer cells Breast Cancer Res. Treat. 36 1995 299 306
61. M.C. Cabot, Z. Zhang, H. Cao, Y. Lavie, A.E. Giuliano, T.Y. Han, and R.C. Jones Tamoxifen activates cellular phospholipase C and D and elicits protein kinase C translocation Int. J. Cancer 70 1997 567 574
62. R.A. Nesbit, R.L. Woods, M.H. Tattersall, R.M. Fox, J.F. Forbes, I.R. MacKay, and M. Goodyear Tamoxifen in malignant melanoma N. Engl. J. Med. 301 1979 1241 1242
63. S.A. Del Prete, L.H. Maurer, J. O'Donnell, R.J. Forcier, and P. LeMarbre Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma Cancer Treat. Rep. 68 1984 1403 1405
64. E.F. McClay, M.J. Mastrangelo, R.E. Bellet, and D. Berd Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma Cancer Treat. Rep. 71 1987 465 469
65. E.F. McClay, and M.E. McClay Tamoxifen: is it useful in the treatment of patients with metastatic melanoma? J. Clin. Oncol. 12 1994 617 626
66. J.J. Rusthoven, I.C. Quirt, N.A. Iscoe, P.B. McCulloch, K.W. James, R.C. Lohmann, J. Jensen, S. Burdette-Radoux, A.J. Bodurtha, H.K. Silver, S. Verma, G.R. Armitage, B. Zee, and K. Bennett Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group J. Clin. Oncol. 14 1996 2083 2090
67. S. Toma, D. Ugolini, and R. Palumbo Tamoxifen in the treatment of metastatic malignant melanoma: still a controversy? Review Int. J. Oncol. 15 1999 321 337
68. H. Matsuoka, M. Tsubaki, Y. Yamazoe, M. Ogaki, T. Satou, T. Itoh, T. Kusunoki, and S. Nishida Tamoxifen inhibits tumor cell invasion and metastasis in mouse melanoma through suppression of PKC/MEK/ERK and PKC/PI3K/Akt pathways Exp. Cell Res. 315 2009 2022 2032
69. M. Hewish, I. Chau, and D. Cunningham Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine Recent Pat. Anticancer Drug Discov. 4 2009 54 72
70. L. Kanter-Lewensohn, L. Girnita, A. Girnita, A. Dricu, G. Olsson, L. Leech, G. Nilsson, A. Hilding, J. Wejde, K. Brismar, and O. Larsson Tamoxifen-induced cell death in malignant melanoma cells: possible involvement of the insulin-like growth factor-1 (IGF-1) pathway Mol. Cell. Endocrinol. 165 2000 131 137
71. S. Mandlekar, and A.N. Kong Mechanisms of tamoxifen-induced apoptosis Apoptosis 6 2001 469 477
72. O. Lavi, M.M. Gottesman, and D. Levy The dynamics of drug resistance: a mathematical perspective Drug Resist. Updat. 15 2012 90 97
73. K.M. Pluchino, M.D. Hall, A.S. Goldsborough, R. Callaghan, and M.M. Gottesman Collateral sensitivity as a strategy against cancer multidrug resistance Drug Resist. Updat. 15 2012 98 105
74. K. Yang, J. Wu, and X. Li Recent advances in the research of P-glycoprotein inhibitors Biosci. Trends 2 2008 137 146
75. S. Nobili, I. Landini, B. Giglioni, and E. Mini Pharmacological strategies for overcoming multidrug resistance Curr. Drug Targets 7 2006 861 879
76. C. Baumert, and A. Hilgeroth Recent advances in the development of P-gp inhibitors Anti Cancer Agents Med. Chem. 9 2009 415 436
77. R.L. Shepard, J. Cao, J.J. Starling, and A.H. Dantzig Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979 Int. J. Cancer 103 2003 121 125
78. M.M. O'Brien, N.J. Lacayo, B.L. Lum, S. Kshirsagar, S. Buck, Y. Ravindranath, M. Bernstein, H. Weinstein, M.N. Chang, R.J. Arceci, B.I. Sikic, and G.V. Dahl Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group Pediatr. Blood Cancer 54 2010 694 702
79. B.C. Shaffer, J.P. Gillet, C. Patel, M.R. Baer, S.E. Bates, and M.M. Gottesman Drug resistance: still a daunting challenge to the successful treatment of AML Drug Resist. Updat. 15 2012 62 69
80. M.D. Hall, M.D. Handley, and M.M. Gottesman Is resistance useless? Multidrug resistance and collateral sensitivity Trends Pharmacol. Sci. 30 2009 546 556
81. R. Callaghan, and C.F. Higgins Interaction of tamoxifen with the multidrug resistance P-glycoprotein Br. J. Cancer 71 1995 294 299
82. T.S. Bekaii-Saab, M.D. Perloff, J.L. Weemhoff, D.J. Greenblatt, and L.L. von Moltke Interactions of tamoxifen, N-desmethyltamoxifen and 4-hydroxytamoxifen with P-glycoprotein and CYP3A Biopharm. Drug Dispos. 25 2004 283 289
83. N.S. Stuart, P. Philip, A.L. Harris, K. Tonkin, S. Houlbrook, J. Kirk, E.A. Lien, and J. Carmichael High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines Br. J. Cancer 66 1992 833 839
84. A.L. Cheng, Y.C. Chen, K.H. Yeh, S.E. Chuang, B.R. Chen, and D.S. Chen Chronic oral etoposide and tamoxifen in the treatment of far-advanced hepatocellular carcinoma Cancer 77 1996 872 877
85. D.L. Trump, D.C. Smith, P.G. Ellis, M.P. Rogers, S.C. Schold, E.P. Winer, T.J. Panella, V.C. Jordan, and R.L. Fine High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine J. Natl. Cancer Inst. 84 1992 1811 1816
86. B.L. Samuels, D.R. Hollis, G.L. Rosner, D.L. Trump, C.L. Shapiro, N.J. Vogelzang, and R.L. Schilsky Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study Clin. Cancer Res. 3 1997 1977 1984
87. J.H. Liu, M.H. Yang, F.S. Fan, C.C. Yen, W.S. Wang, Y.H. Chang, K.K. Chen, and P.M. Chen Tamoxifen and colchicine-modulated vinblastine followed by 5-fluorouracil in advanced renal cell carcinoma: a phase II study Urology 57 2001 650 654
88. D.C. Smith, and D.L. Trump A phase I trial of high-dose oral tamoxifen and CHOPE Cancer Chemother. Pharmacol. 36 1995 65 68
89. E. Berman, M. McBride, S. Lin, C. Menedez-Botet, and W. Tong Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia Leukemia 9 1995 1631 1637
90. G. Weinlander, G. Kornek, M. Raderer, M. Hejna, C. Tetzner, and W. Scheithauer Treatment of advanced colorectal cancer with doxorubicin combined with two potential multidrug-resistance-reversing agents: high-dose oral tamoxifen and dexverapamil J. Cancer Res. Clin. Oncol. 123 1997 452 455
91. A. El-Yazigi, J. Berry, A. Ezzat, and F.A. Wahab Effect of tamoxifen on the pharmacokinetics of doxorubicin in patients with non-Hodgkin's lymphoma Ther. Drug Monit. 19 1997 632 636
92. F.E. Nathan, D. Berd, T. Sato, and M.J. Mastrangelo Paclitaxel and tamoxifen: an active regimen for patients with metastatic melanoma Cancer 88 2000 79 87
93. A. Lucci, W.I. Cho, T.Y. Han, A.E. Giuliano, D.L. Morton, and M.C. Cabot Glucosylceramide: a marker for multiple-drug resistant cancers Anticancer Res. 18 1998 475 480
94. D.W. Shen, C. Cardarelli, J. Hwang, M. Cornwell, N. Richert, S. Ishii, I. Pastan, and M.M. Gottesman Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins J. Biol. Chem. 261 1986 7762 7770
95. V. Gouaze, J.Y. Yu, R.J. Bleicher, T.Y. Han, Y.Y. Liu, H. Wang, M.M. Gottesman, A. Bitterman, A.E. Giuliano, and M.C. Cabot Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy Mol. Cancer Ther. 3 2004 633 639
96. R. Bose, M. Verheij, A. Haimovitz-Friedman, K. Scotto, Z. Fuks, and R. Kolesnick Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals Cell 82 1995 405 414
97. D.L. Morton, M.H. Ravindranath, and R.F. Irie Tumor gangliosides as targets for active specific immunotherapy of melanoma in man Prog. Brain Res. 101 1994 251 275
98. Y. Lavie, H. Cao, A. Volner, A. Lucci, T.Y. Han, V. Geffen, A.E. Giuliano, and M.C. Cabot Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells J. Biol. Chem. 272 1997 1682 1687
99. Y. Jiang, N.A. DiVittore, J.M. Kaiser, S.S. Shanmugavelandy, J.L. Fritz, Y. Heakal, H.R. Tagaram, H. Cheng, M.C. Cabot, K.F. Staveley-O'Carroll, M.A. Tran, T.E. Fox, B.M. Barth, and M. Kester Combinatorial therapies improve the therapeutic efficacy of nanoliposomal ceramide for pancreatic cancer Cancer Biol. Ther. 12 2011 574 585
100. A. Lucci, A.E. Giuliano, T.Y. Han, T. Dinur, Y.Y. Liu, A. Senchenkov, and M.C. Cabot Ceramide toxicity and metabolism differ in wild-type and multidrug-resistant cancer cells Int. J. Oncol. 15 1999 535 540
101. S.A. Morad, J.P. Madigan, J.C. Levin, N. Abdelmageed, R. Karimi, D.W. Rosenberg, M. Kester, S.S. Shanmugavelandy, and M.C. Cabot Tamoxifen magnifies therapeutic impact of ceramide in human colorectal cancer cells independent of p53 Biochem. Pharmacol. 85 2013 1057 1065
102. F. Scarlatti, C. Bauvy, A. Ventruti, G. Sala, F. Cluzeaud, A. Vandewalle, R. Ghidoni, and P. Codogno Ceramide-mediated macroautophagy involves inhibition of protein kinase B and up-regulation of beclin 1 J. Biol. Chem. 279 2004 18384 18391
103. S.J. Furlong, J.S. Mader, and D.W. Hoskin Lactoferricin-induced apoptosis in estrogen-nonresponsive MDA-MB-435 breast cancer cells is enhanced by C6 ceramide or tamoxifen Oncol. Rep. 15 2006 1385 1390
104. G. Gucluler, O. Piskin, and Y. Baran The roles of antiapoptotic sphingosine kinase-1 and glucosylceramide genes in drug induced cell death of MCF-7 breast cancer cells J. BUON 16 2011 646 651
105. R. Perez-Tomas Multidrug resistance: retrospect and prospects in anti-cancer drug treatment Curr. Med. Chem. 13 2006 1859 1876
106. A. van Helvoort, M.L. Giudici, M. Thielemans, and G. van Meer Transport of sphingomyelin to the cell surface is inhibited by brefeldin A and in mitosis, where C6-NBD-sphingomyelin is translocated across the plasma membrane by a multidrug transporter activity J. Cell Sci. 110 Pt 1 1997 75 83
107. M.F. De Rosa, D. Sillence, C. Ackerley, and C. Lingwood Role of multiple drug resistance protein 1 in neutral but not acidic glycosphingolipid biosynthesis J. Biol. Chem. 279 2004 7867 7876
108. J.A. Shabbits, and L.D. Mayer P-glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs Mol. Cancer Ther. 1 2002 205 213
109. A.G. Charles, T.Y. Han, Y.Y. Liu, N. Hansen, A.E. Giuliano, and M.C. Cabot Taxol-induced ceramide generation and apoptosis in human breast cancer cells Cancer Chemother. Pharmacol. 47 2001 444 450
110. J. Turzanski, M. Grundy, S. Shang, N. Russell, and M. Pallis P-glycoprotein is implicated in the inhibition of ceramide-induced apoptosis in TF-1 acute myeloid leukemia cells by modulation of the glucosylceramide synthase pathway Exp. Hematol. 33 2005 62 72
111. H. Sietsma, A.J. Dijkhuis, W. Kamps, and J.W. Kok Sphingolipids in neuroblastoma: their role in drug resistance mechanisms Neurochem. Res. 27 2002 665 674
112. J.V. Chapman, V. Gouaze-Andersson, and M.C. Cabot Expression of P-glycoprotein in HeLa cells confers resistance to ceramide cytotoxicity Int. J. Oncol. 37 2010 1591 1597
113. H. Sietsma, R.J. Veldman, D. Kolk, B. Ausema, W. Nijhof, W. Kamps, E. Vellenga, and J.W. Kok 1-Phenyl-2-decanoylamino-3-morpholino-1-propanol chemosensitizes neuroblastoma cells for taxol and vincristine Clin. Cancer Res. 6 2000 942 948
114. L. Chai, R.P. McLaren, A. Byrne, W.L. Chuang, Y. Huang, M.R. Dufault, J. Pacheco, S. Madhiwalla, X. Zhang, M. Zhang, B.A. Teicher, K. Carter, S.H. Cheng, J.P. Leonard, Y. Xiang, M. Vasconcelles, M.A. Goldberg, D.P. Copeland, K.W. Klinger, J. Lillie, S.L. Madden, and Y.A. Jiang The chemosensitizing activity of inhibitors of glucosylceramide synthase is mediated primarily through modulation of P-gp function Int. J. Oncol. 38 2011 701 711
115. E. Norris-Cervetto, R. Callaghan, F.M. Platt, R.A. Dwek, and T.D. Butters Inhibition of glucosylceramide synthase does not reverse drug resistance in cancer cells J. Biol. Chem. 279 2004 40412 40418
116. S.A. Morad, J.C. Levin, S.S. Shanmugavelandy, M. Kester, G. Fabrias, C. Bedia, and M.C. Cabot Ceramide-antiestrogen nanoliposomal combinations - novel impact of hormonal therapy in hormone-insensitive breast cancer Mol. Cancer Ther. 11 2012 2352 2361
117. J.V. Chapman, V. Gouaze-Andersson, M.C. Messner, M. Flowers, R. Karimi, M. Kester, B.M. Barth, X. Liu, Y.Y. Liu, A.E. Giuliano, and M.C. Cabot Metabolism of short-chain ceramide by human cancer cells - implications for therapeutic approaches Biochem. Pharmacol. 80 2010 308 315
118. H. Wang, A.G. Charles, A.J. Frankel, and M.C. Cabot Increasing intracellular ceramide: an approach that enhances the cytotoxic response in prostate cancer cells Urology 61 2003 1047 1052
119. S. Gatt Enzymic hydrolysis and synthesis of ceramides J. Biol. Chem. 238 1963 3131 3133
120. M.T. Dimanche-Boitrel, and A. Rebillard Sphingolipids and response to chemotherapy Handb. Exp. Pharmacol. 2013 73 91
121. T.E. Fox, M.C. Bewley, K.A. Unrath, M.M. Pedersen, R.E. Anderson, D.Y. Jung, L.S. Jefferson, J.K. Kim, S.K. Bronson, J.M. Flanagan, and M. Kester Circulating sphingolipid biomarkers in models of type 1 diabetes J. Lipid Res. 52 2011 509 517
122. S.J. Furlong, N.D. Ridgway, and D.W. Hoskin Modulation of ceramide metabolism in T-leukemia cell lines potentiates apoptosis induced by the cationic antimicrobial peptide bovine lactoferricin Int. J. Oncol. 32 2008 537 544
123. R.J. Watters, T.E. Fox, S.F. Tan, S. Shanmugavelandy, J.E. Choby, K. Broeg, J. Liao, M. Kester, M.C. Cabot, T.P. Loughran, and X. Liu Targeting glucosylceramide synthase synergizes with C6-ceramide nanoliposomes to induce apoptosis in natural killer cell leukemia Leuk. Lymphoma 54 2013 1288 1296
124. S.A. Morad, J.C. Levin, S.F. Tan, T.E. Fox, D.J. Feith, and M.C. Cabot Novel off-target effect of tamoxifen - inhibition of acid ceramidase activity in cancer cells Biochim. Biophys. Acta 1831 2013 1657 1664
125. D.E. Bowles, A. Contreras-Ramos, and R.W. Sites Gynomorphic mandible morphology in the dobsonfly, Corydalus cornutus J. Insect Sci. 7 2007 1 5
126. D. Shida, K. Takabe, D. Kapitonov, S. Milstien, and S. Spiegel Targeting SphK1 as a new strategy against cancer Curr. Drug Targets 9 2008 662 673
127. X. Liu, S. Elojeimy, L.S. Turner, A.E. Mahdy, Y.H. Zeidan, A. Bielawska, J. Bielawski, J.Y. Dong, A.M. El-Zawahry, G.W. Guo, Y.A. Hannun, D.H. Holman, S. Rubinchik, Z. Szulc, T.E. Keane, M. Tavassoli, and J.S. Norris Acid ceramidase inhibition: a novel target for cancer therapy Front. Biosci. 13 2008 2293 2298
128. T.H. Beckham, P. Lu, J.C. Cheng, D. Zhao, L.S. Turner, X. Zhang, S. Hoffman, K.E. Armeson, A. Liu, T. Marrison, Y.A. Hannun, and X. Liu Acid ceramidase-mediated production of sphingosine 1-phosphate promotes prostate cancer invasion through upregulation of cathepsin B Int. J. Cancer 131 2012 2034 2043
129. A.E. Mahdy, J.C. Cheng, J. Li, S. Elojeimy, W.D. Meacham, L.S. Turner, A. Bai, C.R. Gault, A.S. McPherson, N. Garcia, T.H. Beckham, A. Saad, A. Bielawska, J. Bielawski, Y.A. Hannun, T.E. Keane, M.I. Taha, H.M. Hammouda, J.S. Norris, and X. Liu Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer Mol. Ther. 17 2009 430 438
130. C. Bedia, J. Casas, N. Andrieu-Abadie, G. Fabrias, and T. Levade Acid ceramidase expression modulates the sensitivity of A375 melanoma cells to dacarbazine J. Biol. Chem. 286 2011 28200 28209
131. G. Musumarra, V. Barresi, D.F. Condorelli, and S. Scire A bioinformatic approach to the identification of candidate genes for the development of new cancer diagnostics Biol. Chem. 384 2003 321 327
132. S.A. Morad, S.F. Tan, D.J. Feith, M. Kester, D.F. Claxton, T.P. Loughran, B.M. Barth, T.E. Fox, and M.C. Cabot Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia - impact on enzyme activity and response to cytotoxics Biochim. Biophys. Acta 1851 2015 919 928
133. S. Elojeimy, D.H. Holman, X. Liu, A. El-Zawahry, M. Villani, J.C. Cheng, A. Mahdy, Y. Zeidan, A. Bielwaska, Y.A. Hannun, and J.S. Norris New insights on the use of desipramine as an inhibitor for acid ceramidase FEBS Lett. 580 2006 4751 4756
134. G. Fabrias, C. Bedia, J. Casas, J.L. Abad, and A. Delgado Ceramidases in hematological malignancies: senseless or neglected target? Anti Cancer Agents Med. Chem. 11 2011 830 843
135. A. Delgado, G. Fabrias, C. Bedia, J. Casas, and J.L. Abad Sphingolipid modulation: a strategy for cancer therapy Anti Cancer Agents Med. Chem. 12 2012 285 302
136. T.E. Dick, J.A. Hengst, T.E. Fox, A.L. Colledge, V.P. Kale, S.S. Sung, A. Sharma, S. Amin, T.P. Loughran Jr., M. Kester, H.G. Wang, and J.K. Yun The apoptotic mechanism of action of the sphingosine kinase 1 selective inhibitor SKI-178 in human acute myeloid leukemia cell lines J. Pharmacol. Exp. Ther. 352 2015 494 508
137. D. Plano, S. Amin, and A.K. Sharma Importance of sphingosine kinase (SphK) as a target in developing cancer therapeutics and recent developments in the synthesis of novel SphK inhibitors J. Med. Chem. 57 2014 5509 5524
138. N.J. Pyne, J. Ohotski, R. Bittman, and S. Pyne The role of sphingosine 1-phosphate in inflammation and cancer Adv. Biol. Regul. 54 2014 121 129
139. L.A. Heffernan-Stroud, and L.M. Obeid Sphingosine kinase 1 in cancer Adv. Cancer Res. 117 2013 201 235
140. S.P. Selvam, and B. Ogretmen Sphingosine kinase/sphingosine 1-phosphate signaling in cancer therapeutics and drug resistance Handb. Exp. Pharmacol. 2013 3 27
141. E. Bonhoure, D. Pchejetski, N. Aouali, H. Morjani, T. Levade, T. Kohama, and O. Cuvillier Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1 Leukemia 20 2006 95 102
142. J.V. Chapman, V. Gouaze-Andersson, R. Karimi, M.C. Messner, and M.C. Cabot P-glycoprotein antagonists confer synergistic sensitivity to short-chain ceramide in human multidrug-resistant cancer cells Exp. Cell Res. 317 2011 1736 1745
143. J.M. Wu, A.M. DiPietrantonio, and T.C. Hsieh Mechanism of fenretinide (4-HPR)-induced cell death Apoptosis 6 2001 377 388
144. M.C. Morales, G. Perez-Yarza, N.N. Rementeria, M.D. Boyano, A. Apraiz, A. Gomez-Munoz, E. Perez-Andres, and A. Asumendi 4-HPR-mediated leukemia cell cytotoxicity is triggered by ceramide-induced mitochondrial oxidative stress and is regulated downstream by Bcl-2 Free Radic. Res. 41 2007 591 601
145. B.J. Maurer, L.S. Metelitsa, R.C. Seeger, M.C. Cabot, and C.P. Reynolds Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)-retinamide in neuroblastoma cell lines J. Natl. Cancer Inst. 91 1999 1138 1146
146. W. Zheng, J. Kollmeyer, H. Symolon, A. Momin, E. Munter, E. Wang, S. Kelly, J.C. Allegood, Y. Liu, Q. Peng, H. Ramaraju, M.C. Sullards, M. Cabot, and A.H. Merrill Jr. Ceramides and other bioactive sphingolipid backbones in health and disease: lipidomic analysis, metabolism and roles in membrane structure, dynamics, signaling and autophagy Biochim. Biophys. Acta 1758 2006 1864 1884
147. J.M. Kraveka, L. Li, Z.M. Szulc, J. Bielawski, B. Ogretmen, Y.A. Hannun, L.M. Obeid, and A. Bielawska Involvement of dihydroceramide desaturase in cell cycle progression in human neuroblastoma cells J. Biol. Chem. 282 2007 16718 16728
148. M. Rahmaniyan, R.W. Curley Jr., L.M. Obeid, Y.A. Hannun, and J.M. Kraveka Identification of dihydroceramide desaturase as a direct in vitro target for fenretinide J. Biol. Chem. 286 2011 24754 24764
149. H. Wang, B.J. Maurer, Y.Y. Liu, E. Wang, J.C. Allegood, S. Kelly, H. Symolon, Y. Liu, A.H. Merrill Jr., V. Gouaze-Andersson, J.Y. Yu, A.E. Giuliano, and M.C. Cabot N-(4-Hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killing Mol. Cancer Ther. 7 2008 2967 2976
150. G. Fabrias, J. Munoz-Olaya, F. Cingolani, P. Signorelli, J. Casas, V. Gagliostro, and R. Ghidoni Dihydroceramide desaturase and dihydrosphingolipids: debutant players in the sphingolipid arena Prog. Lipid Res. 51 2012 82 94
151. B.J. Maurer, L. Melton, C. Billups, M.C. Cabot, and C.P. Reynolds Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism J. Natl. Cancer Inst. 92 2000 1897 1909
152. N.S. Radin Chemotherapy by slowing glucosphingolipid synthesis Biochem. Pharmacol. 57 1999 589 595
153. S.A.F. Morad, J.C. Levin, M. Kester, S.S. Shanmugavelandy, and M.C. Cabot Ceramide-antiestrogen nanoliposomal combinations - novel impact of hormonal therapy in hormone-insensitive breast cancer Mol. Cancer Ther. 11 11 2012 2352 2361
154. S.A.F. Morad, L.C. Bridges, and M.C. Cabot Abstract A31: revisited use of tamoxifen for improving melanoma therapy Clin. Cancer Res. 21 2015 A31
155. A.B. Awad, S.L. Barta, C.S. Fink, and P.G. Bradford beta-Sitosterol enhances tamoxifen effectiveness on breast cancer cells by affecting ceramide metabolism Mol. Nutr. Food Res. 52 2008 419 426
156. C.G. Roberts, E. Gurisik, T.J. Biden, R.L. Sutherland, and A.J. Butt Synergistic cytotoxicity between tamoxifen and the plant toxin persin in human breast cancer cells is dependent on Bim expression and mediated by modulation of ceramide metabolism Mol. Cancer Ther. 6 2007 2777 2785
157. H. Devalapally, Z. Duan, M.V. Seiden, and M.M. Amiji Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles Clin. Cancer Res. 14 2008 3193 3203
158. S.J. O'Day, P.D. Boasberg, T.S. Kristedja, M. Martin, H.J. Wang, P. Fournier, M. Cabot, M.W. DeGregorio, and G. Gammon High-dose tamoxifen added to concurrent biochemotherapy with decrescendo interleukin-2 in patients with metastatic melanoma Cancer 92 2001 609 619
159. R.C. Bergan, E. Reed, C.E. Myers, D. Headlee, O. Brawley, H.K. Cho, W.D. Figg, A. Tompkins, W.M. Linehan, D. Kohler, S.M. Steinberg, and M.V. Blagosklonny A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer Clin. Cancer Res. 5 1999 2366 2373
160. S.R. Johnston, B.P. Haynes, N.P. Sacks, J.A. McKinna, L.J. Griggs, M. Jarman, M. Baum, I.E. Smith, and M. Dowsett Effect of oestrogen receptor status and time on the intra-tumoural accumulation of tamoxifen and N-desmethyltamoxifen following short-term therapy in human primary breast cancer Breast Cancer Res. Treat. 28 1993 241 250
161. A. Lucci, T.Y. Han, Y.Y. Liu, A.E. Giuliano, and M.C. Cabot Multidrug resistance modulators and doxorubicin synergize to elevate ceramide levels and elicit apoptosis in drug-resistant cancer cells Cancer 86 1999 300 311
162. M. Mimeault, G. Venkatraman, S.L. Johansson, E. Moore, J.P. Henichart, P. Depreux, M.F. Lin, and S.K. Batra Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide Int. J. Cancer 120 2007 160 169
163. A. Lucci, T.Y. Han, Y.Y. Liu, A.E. Giuliano, and M.C. Cabot Modification of ceramide metabolism increases cancer cell sensitivity to cytotoxics Int. J. Oncol. 15 1999 541 546